XML 24 R2.htm IDEA: XBRL DOCUMENT v3.23.3Close
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Total revenue $ 2,530.3 $ 2,508.5 $ 7,449.3 $ 7,629.4 Close
Cost and expenses:        
Cost of sales, excluding amortization and impairment of acquired intangible assets 659.6 469.5 1,915.1 1,707.4
Research and development 736.3 549.2 1,891.1 1,629.5
Selling, general and administrative 788.2 563.3 1,941.2 1,770.8
Amortization and impairment of acquired intangible assets 60.9 56.5 164.0 190.9
Collaboration profit sharing/(loss reimbursement) 50.5 45.3 164.5 (42.6)
(Gain) loss on fair value remeasurement of contingent consideration 0.0 (2.1) 0.0 (13.7)
Restructuring charges 76.0 15.4 120.0 124.1
Gain on sale of building 0.0 503.7 0.0 503.7
Other (income) expense, net 300.0 (56.0) 248.2 (221.3)
Total cost and expense 2,671.5 1,137.4 6,444.1 4,641.4 Close
Income (loss) before income tax (benefit) expense and equity in loss of investee, net of tax (141.2) 1,371.1 1,005.2 2,988.0 Close
Income tax (benefit) expense (72.9) 236.2 92.6 578.5 Close
Equity in (income) loss of investee, net of tax 0.0 0.0 0.0 (2.6) Close
Net income (loss) (68.3) 1,134.9 912.6 2,412.1 Close
Net income (loss) attributable to noncontrolling interests, net of tax (0.2) 0.2 1.2 (84.4)
Net income (loss) attributable to Biogen Inc. $ (68.1) $ 1,134.7 $ 911.4 $ 2,496.5
Net income per share:        
Basic earnings (loss) per share attributable to Biogen Inc. $ (0.47) $ 7.86 $ 6.30 $ 17.12
Diluted earnings (loss) per share attributable to Biogen Inc. $ (0.47) $ 7.84 $ 6.26 $ 17.07
Weighted-average shares used in calculating:        
Basic earnings (loss) per share attributable to Biogen Inc. 144,800 144,400 144,700 145,800
Diluted earnings (loss) per share attributable to Biogen Inc. 144,800 144,800 145,500 146,200
Product, net        
Total revenue $ 1,805.2 $ 1,962.1 $ 5,414.3 $ 6,083.3
LEQEMBI Collaboration        
Cost and expenses:        
Selling, general and administrative 38.7      
Revenue from anti-CD20 therapeutic programs        
Total revenue 420.9 416.9 1,253.8 1,252.6
Contract manufacturing, royalty and other revenue        
Total revenue $ 304.2 $ 129.5 $ 781.2 $ 293.5